Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro selection of mutant HDM2 resistant to Nutlin inhibition.

PloS one - 1 Jan 2013

Wei Siau Jia, Joseph Thomas, Sim Adelene Y L, Yurlova Larisa, Zolghadr Kourosh, Lane David, Verma Chandra, Ghadessy Farid

Abstract excerpt

HDM2 binds to the p53 tumour suppressor and targets it for proteosomal degradation. Presently in clinical trials, the small molecule Nutlin-3A competitively binds to HDM2 and abrogates its repressive function. Using a novel in vitro selection methodology, we simulated the emergence of resistance by evolving HDM2 mutants capable of binding p53 in the presence of Nutlin concentrations that inhibit the wild-type...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Fibroblasts
Share to Gene Library

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Molecular Docking Simulation

Share to Piperazines

Share to Protein Structure, Secondary

Share to Proto-Oncogene Proteins c-mdm2

Source

Open in PubMed Open full text

Identifiers

PMID: 23653682
DOI: 10.1371/journal.pone.0062564
PMCID: PMC3641235

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro selection of mutant HDM2 resistant to Nutlin inhibition.PMID 23653682Read ↗

Inhibition of nutlin-resistant HDM2 mutants by stapled peptides.Semantic proximity Read ↗

Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3Semantic proximity Read ↗

Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides.Semantic proximity Read ↗

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?Semantic proximity Read ↗

Targeting the p53–MDM2 interaction to treat cancerSemantic proximity Read ↗

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.Semantic proximity Read ↗

Nutlin-3a selects for cells harbouring TP53 mutations.Semantic proximity Read ↗

Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITASemantic proximity Read ↗

Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.Semantic proximity Read ↗

<i>TP53</i> mutations and drug sensitivity in acute myeloid leukaemia cells with acquired MDM2 inhibitor resistanceSemantic proximity Read ↗

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097Semantic proximity Read ↗

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.